Adynamic Bone Disease in Dialysis Patients

Introduction to Adynamic Bone Disease

The American Journal of Kidney Diseases recommends that patients with adynamic bone disease should have a parathyroid hormone (PTH) level between 150-600 pg/mL, as this range is associated with improved bone health 1, 2, 3
The National Kidney Foundation suggests that adynamic bone disease is a common condition in dialysis patients, characterized by low PTH levels and abnormal bone histology, which can increase the risk of fractures and cardiovascular disease 1, 5

The American Journal of Kidney Diseases suggests that patients with PTH levels <100 pg/mL have a 4-fold increased risk of hip fracture compared to the general population, and recommends reducing magnesium exposure and adjusting calcium and phosphate levels to improve bone health 1, 4
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that patients with adynamic bone disease should be managed with a target PTH level of 150-600 pg/mL, and that magnesium levels should be monitored regularly to avoid hypermagnesemia 1, 2, 3

The American Journal of Kidney Diseases recommends that patients with adynamic bone disease should avoid high calcium and magnesium dialysate, and should not use calcium-based phosphate binders or vitamin D, as these can suppress PTH levels and worsen bone disease 1, 2, 3
The National Kidney Foundation suggests that regular monitoring of PTH and magnesium levels is essential to prevent and manage adynamic bone disease in dialysis patients, and recommends that patients with high magnesium levels should be switched to a low-magnesium dialysate 1, 5